Revenue and Profitability - The group's revenue from medical supplies was HKD 54,985 thousand in 2024, slightly down from HKD 55,061 thousand in 2023, representing a decrease of approximately 0.14%[13] - Revenue from medical equipment increased significantly to HKD 22,899 thousand in 2024 from HKD 17,476 thousand in 2023, marking an increase of about 30.9%[13] - Total revenue for the group reached HKD 81,747 thousand in 2024, compared to HKD 76,545 thousand in 2023, reflecting a growth of approximately 6.5%[13] - The group's revenue increased by approximately 6.8% from about HKD 76,700,000 for the year ended March 31, 2023, to approximately HKD 81,900,000 for the year ended March 31, 2024[38] - The pre-tax profit for 2024 reached HKD 39,962,000, an increase from HKD 37,189,000 in 2023, representing a growth of approximately 4.8%[16] - The group's net profit increased by approximately HKD 200,000 from about HKD 7,600,000 to approximately HKD 7,800,000, attributed to revenue growth and a lesser increase in administrative expenses[43] - Net profit attributable to equity shareholders rose to HKD 7,855,000 from HKD 7,562,000, representing a growth of 3.9%[116] Government Support and Other Income - The group received government subsidies totaling HKD 2,510 thousand in 2024, up from HKD 1,022 thousand in 2023, indicating a substantial increase of about 145%[13] - The group reported bank interest income of HKD 1,661 thousand in 2024, a significant rise from HKD 438 thousand in 2023, representing an increase of approximately 279%[13] - Other income increased significantly to HKD 4,239,000 from HKD 1,475,000, indicating enhanced revenue streams[116] Expenses and Liabilities - Research and development expenses for 2024 amounted to HKD 4,080,000, significantly higher than HKD 2,481,000 in 2023, indicating an increase of about 64.5%[16] - Administrative and other operating expenses increased by approximately HKD 4,900,000 or 16.0% from about HKD 30,500,000 to approximately HKD 35,400,000, primarily due to increased marketing activities and overall salary increases[41] - The total liabilities for trade payables decreased to HKD 3,875,000 in 2024 from HKD 5,969,000 in 2023, indicating a reduction of approximately 35%[29] - The deferred tax expense for 2024 was HKD 311,000, compared to HKD 1,856,000 in 2023, reflecting a significant decrease[18] Shareholder Information - The interim dividend declared for 2024 is HKD 0.25 per share, down from HKD 0.4 per share in 2023, totaling HKD 2,000,000 compared to HKD 3,200,000 in the previous year[19] - The average number of ordinary shares outstanding remained stable at 800,000 for both 2024 and 2023[21] - The company reported a significant increase in other assets, with financial assets measured at fair value through profit or loss amounting to HKD 2,690,000, compared to HKD 3,187,000 in the previous year[100] Assets and Financial Position - As of March 31, 2024, current assets were approximately HKD 104,200,000, compared to approximately HKD 101,600,000 in 2023, while current liabilities decreased to approximately HKD 11,200,000 from about HKD 15,900,000[46] - The net value of current assets reached HKD 92,976,000, up from HKD 85,752,000 in the previous year, indicating an increase of about 8.5%[100] - The company's equity attributable to owners was HKD 103,326,000, compared to HKD 98,671,000 in 2023, reflecting a growth of approximately 4.5%[100] - The total liabilities decreased from HKD 15,889,000 to HKD 11,219,000, showing a reduction of about 29.5%[100] Workforce and Operational Capacity - As of March 31, 2024, the group had a total of 46 employees, an increase from 41 employees in 2023, with employee costs amounting to approximately HKD 21.2 million compared to HKD 18.4 million in 2023[61] - The group has expanded its workforce by hiring seven product representatives, two engineers, and several other roles to enhance operational capacity[64] Strategic Initiatives and Future Outlook - The group established a joint venture to promote autonomous robotic solutions in the healthcare sector, supporting future business growth[36] - The group is optimistic about the healthcare industry's prospects due to an increasing elderly population and rising health awareness among Hong Kong citizens[37] - The company is committed to exploring new strategies for market expansion and product development in the upcoming fiscal year[116] Governance and Compliance - The board has adopted the corporate governance code principles and believes it has complied with all provisions except for the separation of the roles of chairman and CEO as of the fiscal year ending March 31, 2024[82] - The audit committee, consisting of two independent non-executive directors and one non-executive director, has reviewed the group's audited financial results for the fiscal year ending March 31, 2024[96] - The group has adhered to the GEM Listing Rules regarding trading standards and has confirmed compliance by all directors and employees[89] - The group has established independent review and control measures to ensure high governance standards and protect shareholder interests[83]
君百延集团(08372) - 2024 - 年度业绩